AdipoPharma, a Strasbourg, France-based biotech company developing a novel and promising Type 2 diabetes drug, raised an undisclosed amount in funding.
Backers included Newton Biocapital, Sambrinvest, Investsud, Okeanos, and dGood Growth Capital.
The company intends to use the funds to accelerate its clinical development.
Founded by CEO and President Vincent Marion, AdipoPharma is developing a novel mechanisms for treating Type 2 diabetes. Its compound, Patas, is a whole-body insulin sensitizer able to treat insulin resistance, the root cause of Type 2 diabetes. It has been designed to work on fat cells known as adipocytes. By restoring glucose uptake and utilization in impaired adipocytes, Patas, reboots healthy lipid biosynthesis, leading to improved glycated hemoglobin (HbA1c) levels as well as addressing the complications of the disease including diabetic neuropathy, cardiovascular dysfunction, liver disease, and muscle loss.
Vincent Marion has also established AdipoPharma’s scientific advisory board, with internationally recognized experts in Type 2 diabetes, including:
- Dr. Paul Zimmet, scientific advisory board chairman and internationally recognized pioneer in diabetes and obesity research
- Dr. G. Alexander (Zan) Fleming, former senior endocrinologist at the FDA
- Dr. Alan Cherrington, past president of the American Diabetes Association
- Dr Ralph DeFronzo, Chief of the Diabetes Division of the Texas Diabetes Institute
AdipoPharma SAS is headquartered in Strasbourg, France, with offices in Pittsburgh Pennsylvania, USA and Gosselies, Belgium.
FinSMEs
12/11/2024